Outcomes and adverse events following intra-arterial chemotherapy for retinoblastoma: A single center study in South India

Table 4 Intra-arterial chemotherapy for retinoblastoma using 29 catheterizations in 17 eyes: Treatment complications

Number	Intra-arterial chemotherapy cycles	Drug used with dose (mg)	Side effects	Fellow eye status	Best corrected visual acuity at last follow-up visit
1	1	M + T (5 + 1)	Nil	Normal	Fixing n following
2	2	M + T (5 + 1)	Nil	Normal	6/6p
3	1	M + T (5 + 1)	Rhegamatogenous retinal detachment, vitreous hemorrhage	Normal	N/A
4	2	M + T (5 + 1)	Subretinal hemorrhage	Normal	Hand movements
5	1	M + T (5 + 1)	Forehead pigmentation	Normal	6/15
6	3	M + T + C (5/7.5 + 1/2 + 30)	Exotropia, vitreous hemorrhage	Normal	Fixing n following
7	3	M + T + C (5/7.5 + 1/2 + 30)	Retinal pigment epithelium degeneration	Enucleated	Fixing n following
8	3	M (5)	Lid edema, vitreous hemorrhage, rhegmatogenous retinal detachment, choroidal ischemia	Normal	N/A
9	2	M (4)	Nil	Normal	6/60
10	1	M + T (5 + 1)	Nil	Normal	Fixing n following
11	1	M + T (5 + 1)	Third nerve palsy with ptosis	Group E, regressed	Not seeing first card (Cardiff)
12	1	M + T (5 + 1)	Nil	Normal	Not seeing first card (Cardiff)
13	1	M + T (5 + 1)	Subretinal bleed	Normal	Fixing n following
14	1	M + T (5 + 1)	Nil	Group D, regressed	Not fixing n following
15	2	M + T (5 + 1)	Nil	Group B, regressed	Fixing n following
16	2	M + T (5 + 1)	Nil	Group C, regressed	Fixing n following
17	2	M (3)	Retinal pigment epithelium degeneration, melphalan toxicity	Group A, regressed	No perception of light

C: Carboplatin; M: Melphalan; N/A: Not applicable; T: Topotecan.